Key features and details
- Mouse monoclonal [BU63] to CD86 (PE/Cy5®)
- Suitable for: Flow Cyt
- Reacts with: Human
- Conjugation: PE/Cy5®. Ex: 496nm, Em: 670nm
- Isotype: IgG1
Product nameAnti-CD86 antibody [BU63] (PE/Cy5®)
See all CD86 primary antibodies
DescriptionMouse monoclonal [BU63] to CD86 (PE/Cy5®)
ConjugationPE/Cy5®. Ex: 496nm, Em: 670nm
Tested applicationsSuitable for: Flow Cytmore details
Species reactivityReacts with: Human
Tissue, cells or virus corresponding to Human CD86. (B-lymphoblastoid cell line ARH 77).
- Flow Cyt: Human peripheral blood cells.
This product or portions thereof is manufactured under license from Carnegie Mellon University under U.S. Patent Number 5, 268, 486 and related patents. Cy and CyDye are trademarks of GE Healthcare Limited.
Storage instructionsShipped at 4°C. Store at +4°C. Store In the Dark.
Storage bufferPreservative: 0.0975% Sodium azide
Concentration information loading...
Purification notesPurified antibody is conjugated with tandem dye PE/Cy5® under optimum conditions. The conjugate is purified by size-exclusion chromatography and adjusted for direct use. No reconstitution is necessary.
- Anti-CD86 antibody [BU63], prediluted (APC) (ab134385)
- Anti-CD86 antibody [BU63] - BSA and Azide free (ab213044)
- Anti-CD86 antibody [BU63] (PE/Cy7®) (ab233571)
- Anti-CD86 antibody [BU63] (ab234000)
- Anti-CD86 antibody [BU63] (PerCP) (ab77131)
- Anti-CD86 antibody [BU63] (PE) (ab77226)
- Anti-CD86 antibody [BU63] (FITC) (ab77276)
Our Abpromise guarantee covers the use of ab234226 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|Flow Cyt||Use 4µl for 106 cells.
(or 100 μl of whole blood).
FunctionReceptor involved in the costimulatory signal essential for T-lymphocyte proliferation and interleukin-2 production, by binding CD28 or CTLA-4. May play a critical role in the early events of T-cell activation and costimulation of naive T-cells, such as deciding between immunity and anergy that is made by T-cells within 24 hours after activation. Isoform 2 interferes with the formation of CD86 clusters, and thus acts as a negative regulator of T-cell activation.
Tissue specificityExpressed by activated B-lymphocytes and monocytes.
Sequence similaritiesContains 1 Ig-like C2-type (immunoglobulin-like) domain.
Contains 1 Ig-like V-type (immunoglobulin-like) domain.
modificationsPolyubiquitinated; which is promoted by MARCH8 and results in endocytosis and lysosomal degradation.
- Information by UniProt
- Activation B7-2 antigen 3 antibody
- Activation B7-2 antigen antibody
- B-lymphocyte activation antigen B7-2 2 antibody
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
ab234226 has not yet been referenced specifically in any publications.